Cell-free Plasma Hypermethylated CASZ1, CDH13 and ING2 Are Promising Biomarkers of Esophageal Cancer

Overview

Journal J Biomed Res

Specialty General Medicine

Date 2018 Oct 26

PMID 30355852

Citations 12

Authors

Huan-Qiang Wang

Cong-Ying Yang

Si-Yuan Wang

Tian Wang

Jing-Ling Han

Kai Wei

Fu-Cun Liu

Ji-da Xu

Xian-Zhen Peng

Jian-Ming Wang

Affiliations

Soon will be listed here.

Abstract

Identifying sensitive and specific biomarkers for early detection of cancer is immensely imperative for early diagnosis and treatment and better clinical outcome of cancer patients. This study aimed to construct a specific DNA methylation pattern of cancer suppressor genes and explore the feasibility of applying cell-free DNA based methylation as a biomarker for early diagnosis of esophageal squamous cell carcinoma (ESCC). We recruited early stage ESCC patients from Yangzhong County, China. The Illumina Infinium 450K Methylation BeadChip was used to construct a genome-wide DNA methylation profile. Then, differentiated genes were selected for the validation study using the Sequenom MassARRAY platform. The frequency of methylation was compared between cancer tissues, matched cell-free DNAs and normal controls. The specific methylation profiles were constructed, and the sensitivity and specificity were calculated. Seven CG sites in three genes CASZ1, CDH13 and ING2 were significantly hypermethylated in ESCC as compared with normal controls. A significant correlation was found between the methylation of DNA extracted from cancer tissues and matched plasma cell-free DNA, either for individual CG site or for cumulative methylation analysis. The sensitivity and specificity reached 100% at an appropriate cut-point using these specific methylation biomarkers. This study revealed that aberrant DNA methylation is a promising biomarker for molecular diagnosis of esophageal cancer. Hypermethylation of CASZ1, CDH13 and ING2 detected in plasma cell-free DNA can be applied as a potential noninvasive biomarker for diagnosis of esophageal cancer.

Citing Articles

DNA methylation markers in esophageal cancer.

Xu Y, Wang Z, Pei B, Wang J, Xue Y, Zhao G Front Genet. 2024; 15:1354195.

PMID: 38774285 PMC: 11106492. DOI: 10.3389/fgene.2024.1354195.

Role of the CASZ1 transcription factor in tissue development and disease.

Liu T, Li T, Ke S Eur J Med Res. 2023; 28(1):562.

PMID: 38053207 PMC: 10696751. DOI: 10.1186/s40001-023-01548-y.

: Current Implications in Cardiovascular Diseases and Cancers.

Jian H, Poetsch A Biomedicines. 2023; 11(7).

PMID: 37509718 PMC: 10377389. DOI: 10.3390/biomedicines11072079.

Transcription factor CASZ1 increases an oncogenic transcriptional process in tumorigenesis and progression of glioma cells.

Mao C, Huang C, Hu Z, Qu S MedComm (2020). 2022; 3(4):e182.

PMID: 36276925 PMC: 9583698. DOI: 10.1002/mco2.182.

Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies.

Zhu H, Liu X Front Oncol. 2021; 11:666340.

PMID: 34434889 PMC: 8381364. DOI: 10.3389/fonc.2021.666340.

References

Kawakami K, Brabender J, Lord R, Groshen S, Greenwald B, Krasna M . Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst. 2000; 92(22):1805-11. DOI: 10.1093/jnci/92.22.1805. View

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer F, Hesch R . DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001; 61(4):1659-65. View

Hibi K, Taguchi M, Nakayama H, Takase T, Kasai Y, Ito K . Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res. 2001; 7(10):3135-8. View

Craven R, Banks R . Laser capture microdissection and proteomics: possibilities and limitation. Proteomics. 2001; 1(10):1200-4. DOI: 10.1002/1615-9861(200110)1:10<1200::AID-PROT1200>3.0.CO;2-Q. View

Belinsky S, Palmisano W, Gilliland F, Crooks L, Divine K, Winters S . Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002; 62(8):2370-7. View

Vizcaino A, Moreno V, Lambert R, Parkin D . Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002; 99(6):860-8. DOI: 10.1002/ijc.10427. View

Shibata Y, Haruki N, Kuwabara Y, Ishiguro H, Shinoda N, Sato A . Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis. 2002; 23(10):1695-9. DOI: 10.1093/carcin/23.10.1695. View

Noguchi T, Takeno S, Kimura Y, Uchida Y, Daa T, Yokoyama S . FHIT expression and hypermethylation in esophageal squamous cell carcinoma. Int J Mol Med. 2003; 11(4):441-7. View

Zhang L, Lu W, Miao X, Xing D, Tan W, Lin D . Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis. 2003; 24(6):1039-44. DOI: 10.1093/carcin/bgg062. View

10.

Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M . Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res. 2003; 63(13):3724-8. View

11.

Wang G . [30-year experiences on early detection and treatment of esophageal cancer in high risk areas]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003; 23(1):69-72. View

12.

Wang J, Xu B, Hsieh C, Jiang Q . Longitudinal trends of stomach cancer and esophageal cancer in Yangzhong County: a high-incidence rural area of China. Eur J Gastroenterol Hepatol. 2005; 17(12):1339-44. DOI: 10.1097/00042737-200512000-00012. View

13.

Guo M, Ren J, House M, Qi Y, Brock M, Herman J . Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2006; 12(15):4515-22. DOI: 10.1158/1078-0432.CCR-05-2858. View

14.

Eckhardt F, Lewin J, Cortese R, Rakyan V, Attwood J, Burger M . DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet. 2006; 38(12):1378-85. PMC: 3082778. DOI: 10.1038/ng1909. View

15.

Dejeux E, Audard V, Cavard C, Gut I, Terris B, Tost J . Rapid identification of promoter hypermethylation in hepatocellular carcinoma by pyrosequencing of etiologically homogeneous sample pools. J Mol Diagn. 2007; 9(4):510-20. PMC: 1975099. DOI: 10.2353/jmoldx.2007.060209. View

16.

Jin Z, Mori Y, Hamilton J, Olaru A, Sato F, Yang J . Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis. Cancer. 2007; 112(1):43-9. DOI: 10.1002/cncr.23135. View

17.

Gronbaek K, Hother C, Jones P . Epigenetic changes in cancer. APMIS. 2007; 115(10):1039-59. DOI: 10.1111/j.1600-0463.2007.apm_636.xml.x. View

18.

Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B . Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer. 2008; 123(10):2331-6. DOI: 10.1002/ijc.23804. View

19.

Taghavi N, Biramijamal F, Sotoudeh M, Khademi H, Malekzadeh R, Moaven O . p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. BMC Cancer. 2010; 10:138. PMC: 2868052. DOI: 10.1186/1471-2407-10-138. View

20.

Liggett T, Melnikov A, Marks J, Levenson V . Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int J Cancer. 2010; 128(2):492-9. PMC: 2970661. DOI: 10.1002/ijc.25363. View